2/24
10:12 am
lexx
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm [Yahoo! Finance]
Medium
Report
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm [Yahoo! Finance]
1/30
09:15 am
lexx
Lexaria Releases Annual Letter from the CEO
Medium
Report
Lexaria Releases Annual Letter from the CEO
1/24
08:02 am
lexx
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
1/22
04:16 pm
lexx
Lexaria Bioscience files for $50M mixed securities shelf [Seeking Alpha]
Medium
Report
Lexaria Bioscience files for $50M mixed securities shelf [Seeking Alpha]
1/15
09:20 am
lexx
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Medium
Report
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
1/14
09:10 am
lexx
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
High
Report
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)